Kissei Pharmaceutical Co (TSE:4547) Cyclically Adjusted Revenue per Share: 円1,775.39 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4547 Kissei Pharmaceutical Co Ltd TSE:4547
79 GF Score
Price 円3,860.00
GF Value 円4,688.48
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kissei Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kissei Pharmaceutical Co TSE:4547 +0.13% 79 Cyclically Adjusted Revenue per Share is 円1,775.39 as of Mar. 2026. GuruFocus rates TSE:4547 with a GF Score™ of 79/100 and a GF Value™ of 円4,688.48 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kissei Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円596.064. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,775.39 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kissei Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kissei Pharmaceutical Co was 5.20% per year. The lowest was 1.70% per year. And the median was 2.90% per year.

As of today (2026-08-04), Kissei Pharmaceutical Co's current stock price is 円3860.00. Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円1,775.39. Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kissei Pharmaceutical Co was 2.84. The lowest was 1.45. And the median was 2.04.


Kissei Pharmaceutical Co  (TSE:4547) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3860.00/1775.39
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kissei Pharmaceutical Co was 2.84. The lowest was 1.45. And the median was 2.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kissei Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kissei Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kissei Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kissei Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,462.88 1,523.99 1,579.45 1,683.95 1,775.39

Kissei Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,707.32 1,729.32 1,761.74 1,775.39 0.00

TSE:4547 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4547
79GF Score
Kissei Pharmaceutical Co Ltd TSE:4547
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kissei Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kissei Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=596.064/112.7000*112.7000
=596.064

Current CPI (Mar. 2026) = 112.7000.

Kissei Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 391.583 98.100 449.861
201609 340.868 98.000 391.998
201612 383.666 98.400 439.422
201703 353.857 98.100 406.521
201706 390.078 98.500 446.313
201709 367.159 98.800 418.814
201712 417.948 99.400 473.871
201803 364.366 99.200 413.952
201806 382.246 99.200 434.265
201809 381.339 99.900 430.199
201812 419.278 99.700 473.948
201903 364.814 99.700 412.383
201906 344.850 99.800 389.425
201909 330.715 100.100 372.343
201912 363.965 100.500 408.148
202003 314.282 100.300 353.136
202006 343.801 99.900 387.852
202009 347.269 99.900 391.764
202012 426.214 99.300 483.729
202103 362.219 99.900 408.629
202106 360.729 99.500 408.585
202109 341.595 100.100 384.593
202112 383.750 100.100 432.054
202203 331.685 101.100 369.742
202206 353.139 101.800 390.951
202209 359.506 103.100 392.981
202212 407.039 104.100 440.666
202303 343.857 104.400 371.194
202306 419.656 105.200 449.574
202309 385.505 106.200 409.100
202312 464.756 106.800 490.431
202403 400.362 107.200 420.903
202406 478.791 108.200 498.704
202409 481.891 108.900 498.706
202412 528.626 110.700 538.177
202503 519.486 111.100 526.967
202506 529.757 111.700 534.500
202509 567.287 112.000 570.833
202512 644.310 113.000 642.599
202603 596.064 112.700 596.064

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,775.39 mean?
Kissei Pharmaceutical Co (TSE:4547) has a Cyclically Adjusted Revenue per Share of 円1,775.39 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kissei Pharmaceutical Co and its competitors.
Is Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kissei Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,775.39. Overall, Kissei Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円1,775.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kissei Pharmaceutical Co and its competitors. Kissei Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,775.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kissei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co (TSE:4547) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,688.48, compared to a current price of 円3,860.00 — trading 17.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,775.39. Kissei Pharmaceutical Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kissei Pharmaceutical Co (TSE:4547), the current Cyclically Adjusted Revenue per Share is 円1,775.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kissei Pharmaceutical Co (TSE:4547) Overvalued in 2026?

Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued. The current stock price of 円3,860.00 is trading 17.7% below its estimated GF Value™ of 円4,688.48. GuruFocus considers Kissei Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4547:

  • Cyclically Adjusted Revenue per Share: 円1,775.39
  • GF Value™: 円4,688.48 vs. price of 円3,860.00 (17.7% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the TSE:4547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kissei Pharmaceutical Co Business Description

Address 19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
79GF Score

Get the complete analysis for TSE:4547

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,860.00
Price
円4,688.48
GF Value